Recombinant Human HRAS protein(Met1-Cys186), His-tagged

• Cat.No.: HRAS-2524H
• Product Overview: Recombinant Human HRAS (P01112) (Met 1-Cys 186) was expressed in Insect Cells, fused with a polyhistidine tag at the C-terminus.

Specification

• Source: Insect Cells
• Species: Human
• Tag: C-His
• Protein length: Met1-Cys186
• Form: Lyophilized from sterile 50mM Tris, 100mM NaCl, pH 8.0, 10% gly Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The recombinant human HRAS consists of 197 amino acids and predicts a molecular mass of 22.45 kDa. It migrates as an approximately 23 kDa band in SDS-PAGE in SDS-PAGE under reducing conditions.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Purity: > 94 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog [ Homo sapiens ]
• Official Symbol: HRAS
• Synonyms: HRAS; v-Ha-ras Harvey rat sarcoma viral oncogene homolog; HRAS1; GTPase HRas; p21ras; H-Ras-1; p19 H-RasIDX protein; c-has/bas p21 protein; transforming protein p21; Ha-Ras1 proto-oncoprotein; c-ras-Ki-2 activated oncogene; GTP- and GDP-binding peptide B; transformation gene: oncogene HAMSV; Ras family small GTP binding protein H-Ras; CTLO; HAMSV; K-RAS; N-RAS; RASH1; C-H-RAS; H-RASIDX; C-BAS/HAS; C-HA-RAS1
• Gene ID: 3265
• mRNA Refseq: NM_001130442
• Protein Refseq: NP_001123914
• MIM: 190020
• UniProt ID: P01112

Reviews

08/15/2019

With their meticulous documentation and support, I am confident that my utilization of the HRAS protein in clinical trials will meet all necessary regulations and guidelines.

06/26/2019

Their comprehensive certificates of analysis and safety data sheets serve as testaments to their commitment to ensuring the safety and integrity of their products.

09/12/2018

Their ability to accommodate the requirements of large-scale experiments and guarantee a steady supply streamlines my research operations, eliminating any concerns related to prospective shortages.

Q&As

Are there targeted therapies specifically designed for HRAS-related cancers?

Research is ongoing, but there are emerging targeted therapies designed to address HRAS-related cancers.

Can HRAS mutations be detected through genetic testing?

Yes, genetic testing can identify HRAS mutations, aiding in the diagnosis and prognosis of certain disorders.

Can HRAS be a potential therapeutic target for non-cancerous diseases?

Yes, there is growing interest in exploring HRAS as a therapeutic target for non-cancerous diseases, such as cardiovascular disorders.

How does HRAS influence the response to certain cancer treatments?

HRAS status can impact the response to certain cancer treatments, affecting the efficacy of targeted therapies and chemotherapy.

How is HRAS involved in the regulation of the cell cycle?

HRAS regulates the cell cycle by influencing the transition between different phases, ensuring proper cell division.